Anticancer effects of β-elemene in gastric cancer cells and its potential underlying proteins: A proteomic study

Liu,Jun-Song; He,Shi-Cai; Zhang,Zheng-Liang; Chen,Rui; Fan,Lin; Qiu,Guang‑Lin; Chang,Shuai; Li,Liang; Che,Xiang-Ming

doi:10.3892/or.2014.3490

Anticancer effects of β-elemene in gastric cancer cells and its potential underlying proteins: A proteomic study

Authors:
- Jun-Song Liu
- Shi-Cai He
- Zheng-Liang Zhang
- Rui Chen
- Lin Fan
- Guang‑Lin Qiu
- Shuai Chang
- Liang Li
- Xiang-Ming Che
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: September 17, 2014 https://doi.org/10.3892/or.2014.3490
Pages: 2635-2647

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is a common malignancy with a poor prognosis. β-elemene is a broad-spectrum anticancer drug extracted from the traditional Chinese medicinal herb Curcuma wenyujin. In the present study, we investigated the anticancer effects of β-elemene in gastric cancer cells and the potential proteins involved. Human SGC7901 and MKN45 gastric cancer cells were treated with different concentrations of β-elemene. Cell viability, clonogenic survival and apoptotic cell death were assessed. β-elemene inhibited viability and decreased clonogenic survival of gastric cancer cells in a dose-dependent manner. Apoptosis induction contributed to the anticancer effects. We then employed a proteomic method, isobaric tags for relative and absolute quantitation (iTRAQ), to detect the proteins altered by β-elemene. In total, 147 upregulated proteins and 86 downregulated proteins were identified in response to β-elemene treatment in SGC7901 gastric cancer cells. Among them, expression of p21-activated protein kinase‑interacting protein 1 (PAK1IP1), Bcl-2-associated transcription factor 1 (BTF) and topoisomerase 2-α (TOPIIα) were validated by western blot analyses and the trends were consistent with iTRAQ results. Top pathways involved in β-elemene treatment in SGC7901 gastric cancer cells included ribosome signaling, peroxisome proliferator-activated receptors (PPARs) signaling pathway, regulation of actin cytoskeleton, phagosome, biosynthesis and metabolism of some amino acids. Collectively, our results suggest a promising therapeutic role of β-elemene in gastric cancer. The differentially expressed proteins provide further insight into the potential mechanisms involved in gastric cancer treatment using β-elemene.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Saka M, Morita S, Fukagawa T and Katai H: Present and future status of gastric cancer surgery. Jpn J Clin Oncol. 41:307–313. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sastre J, García-Saenz JA and Diaz-Rubio E: Chemotherapy for gastric cancer. World J Gastroenterol. 12:204–213. 2006.
4	Smalley SR, Benedetti JK, Haller DG, et al: Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 30:2327–2333. 2012. View Article : Google Scholar
5	Sakamoto J, Teramukai S, Nakazato H, et al: Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother. 25:405–412. 2002. View Article : Google Scholar
6	Dassen AE, Lemmens VE, van de Poll-Franse LV, et al: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 46:1101–1110. 2010. View Article : Google Scholar : PubMed/NCBI
7	Zhang H, Sun LL, Meng YL, et al: Survival trends in gastric cancer patients of Northeast China. World J Gastroenterol. 17:3257–3262. 2011.PubMed/NCBI
8	Yoo CH, Noh SH, Shin DW, Choi SH and Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg. 87:236–242. 2000. View Article : Google Scholar : PubMed/NCBI
9	D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M and Karpeh MS: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 240:808–816. 2004.PubMed/NCBI
10	Di Costanzo F, Gasperoni S, Manzione L, et al: Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 100:388–398. 2008.PubMed/NCBI
11	GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X, Oba K, Burzykowski T, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
12	Gan T, Wu Z, Tian L and Wang Y: Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev. 1:CD0050962010. View Article : Google Scholar
13	Tan W, Lu J, Huang M, et al: Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med. 6:272011. View Article : Google Scholar : PubMed/NCBI
14	Lee RX, Li QQ and Reed E: β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells. Anticancer Res. 32:3103–3113. 2012.
15	Lu X, Wang Y, Luo H, et al: β-elemene inhibits the proliferation of T24 bladder carcinoma cells through upregulation of the expression of Smad4. Mol Med Rep. 7:513–518. 2013.
16	Zhan YH, Liu J, Qu XJ, et al: β-elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/mTOR signalling pathways. Asian Pac J Cancer Prev. 13:2739–2744. 2012.
17	Xu HB, Li L, Fu J, Mao XP and Xu LZ: Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene. Pharmacology. 89:303–312. 2012.PubMed/NCBI
18	Li QQ, Lee RX, Liang H, Zhong Y and Reed E: Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol. 30:1–13. 2013.
19	Wang B, Peng XX, Sun R, et al: Systematic review of β-elemene injection as adjunctive treatment for lung cancer. Chin J Integr Med. 18:813–823. 2012.
20	Xu HB, Zheng LP, Li L, Xu LZ and Fu J: Elemene, one ingredient of a Chinese herb, against malignant tumors: a literature-based meta-analysis. Cancer Invest. 31:156–166. 2013. View Article : Google Scholar : PubMed/NCBI
21	Li QQ, Wang G, Huang F, Banda M and Reed E: Antineoplastic effect of β-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol. 62:1018–1027. 2010.
22	Wang G, Li X, Huang F, et al: Antitumor effect of β-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci. 62:881–893. 2005.
23	García-Sáez AJ: The secrets of the Bcl-2 family. Cell Death Differ. 19:1733–1740. 2012.
24	Kasof GM, Goyal L and White E: Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol. 19:4390–4404. 1999.PubMed/NCBI
25	Liu H, Lu ZG, Miki Y and Yoshida K: Protein kinase C δ induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol. 27:8480–8491. 2007.
26	Sarras H, Alizadeh Azami S and McPherson JP: In search of a function for BCLAF1. Sci World J. 10:1450–1461. 2010. View Article : Google Scholar : PubMed/NCBI
27	Lee YY, Yu YB, Gunawardena HP, Xie L and Chen X: BCLAF1 is a radiation-induced H2AX-interacting partner involved in γH2AX-mediated regulation of apoptosis and DNA repair. Cell Death Dis. 3:e3592012. View Article : Google Scholar : PubMed/NCBI
28	Kataoka T, Holler N, Micheau O, et al: Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. J Biol Chem. 276:19548–19554. 2001. View Article : Google Scholar : PubMed/NCBI
29	Kim JY, So KJ, Lee S and Park JH: Bcl-rambo induces apoptosis via interaction with the adenine nucleotide translocator. FEBS Lett. 586:3142–3149. 2012. View Article : Google Scholar : PubMed/NCBI
30	Xia C, Ma W, Stafford LJ, Marcus S, Xiong WC and Liu M: Regulation of the p21-activated kinase (PAK) by a human Gβ-like WD-repeat protein, hPIP1. Proc Natl Acad Sci USA. 98:6174–6179. 2001.PubMed/NCBI
31	Dummler B, Ohshiro K, Kumar R and Field J: Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 28:51–63. 2009. View Article : Google Scholar
32	Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB and Jacks T: Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell. 12:841–849. 2003. View Article : Google Scholar : PubMed/NCBI
33	Hirokawa Y, Nakajima H, Hanemann CO, et al: Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol Ther. 4:379–381. 2005. View Article : Google Scholar : PubMed/NCBI
34	Yu W, Qiu Z, Gao N, et al: PAK1IP1, a ribosomal stress-induced nucleolar protein, regulates cell proliferation via the p53-MDM2 loop. Nucleic Acids Res. 39:2234–2248. 2011. View Article : Google Scholar : PubMed/NCBI
35	Dai MS and Lu H: Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 279:44475–44482. 2004. View Article : Google Scholar : PubMed/NCBI
36	Chen D, Zhang Z, Li M, et al: Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 26:5029–5037. 2007. View Article : Google Scholar : PubMed/NCBI
37	Dai MS, Sun XX and Lu H: Ribosomal protein L11 associates with c-Myc at 5 S rRNA and tRNA genes and regulates their expression. J Biol Chem. 285:12587–12594. 2010. View Article : Google Scholar : PubMed/NCBI
38	Zhou X, Hao Q, Liao JM, Liao P and Lu H: Ribosomal protein S14 negatively regulates c-Myc activity. J Biol Chem. 288:21793–21801. 2013. View Article : Google Scholar : PubMed/NCBI
39	Shi Y, Zhai H, Wang X, et al: Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. Exp Cell Res. 296:337–346. 2004. View Article : Google Scholar : PubMed/NCBI
40	Lopez CD, Martinovsky G and Naumovski L: Inhibition of cell death by ribosomal protein L35a. Cancer Lett. 180:195–202. 2002. View Article : Google Scholar : PubMed/NCBI
41	Marenholz I, Lovering RC and Heizmann CW: An update of the S100 nomenclature. Biochim Biophys Acta. 1763:1282–1283. 2006. View Article : Google Scholar : PubMed/NCBI
42	Gross SR, Sin CG, Barraclough R and Rudland PS: Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci. 71:1551–1579. 2014. View Article : Google Scholar : PubMed/NCBI
43	Madureira PA, O’Connell PA, Surette AP, Miller VA and Waisman DM: The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis. J Biomed Biotechnol. 2012:3536872012. View Article : Google Scholar : PubMed/NCBI
44	El-Rifai W, Moskaluk CA, Abdrabbo MK, et al: Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 62:6823–6826. 2002.PubMed/NCBI
45	Domoto T, Miyama Y, Suzuki H, et al: Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci. 98:77–82. 2007. View Article : Google Scholar : PubMed/NCBI
46	Yang X, Popescu NC and Zimonjic DB: DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res. 71:2916–2925. 2011. View Article : Google Scholar : PubMed/NCBI
47	Shang J, Zhang Z, Song W, et al: S100A10 as a novel biomarker in colorectal cancer. Tumour Biol. 34:3785–3790. 2013. View Article : Google Scholar : PubMed/NCBI
48	Oue N, Hamai Y, Mitani Y, et al: Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 64:2397–2405. 2004. View Article : Google Scholar